BMSN. $$$ Here this what I found : Dr Suhy h
Post# of 5066
Posted On: 09/17/2013 12:44:38 PM
BMSN. $$$ Here this what I found :
Dr Suhy has had significant experience in development of DNA-based constructs.
David Suhy leads all of Tacere’s therapeutic development programs. He was one of the inventors of TT-033 and has directed development of the TT-03x series of compounds which target the Hepatitis C virus (HCV), from the drawing board through to Investigational New Drug (IND) enabling studies. Dr Suhy will continue to lead the program as TT-034 is poised to enter the clinic in 2013.
Dr Suhy has held other distinguished roles with US-based biotechnology companies. He served as Principal Scientist at Antara Biosciences, where he was developing two molecular diagnostics platforms, based on electrochemistry and RFID tags as chip-based nucleic acid detection modalities.
He also led the Target Validation Group at PPD Discovery, a company with proprietary technology surrounding the use of genetic suppressor elements to identify ‘druggable’ genomic targets for large pharmaceutical companies.
Dr Suhy holds a BS in Biochemistry and Biophysics from the University of Pittsburgh, earned his PhD in Biochemistry, Molecular Biology and Cell Biology at Northwestern University, and conducted his post-doctoral work at Stanford University.
BMSN is going bigtime, Koos knows the people he must have on board. Its comming guys! $$$
BMSN. Post by Jobrano. BMSN
Dr Suhy has had significant experience in development of DNA-based constructs.
David Suhy leads all of Tacere’s therapeutic development programs. He was one of the inventors of TT-033 and has directed development of the TT-03x series of compounds which target the Hepatitis C virus (HCV), from the drawing board through to Investigational New Drug (IND) enabling studies. Dr Suhy will continue to lead the program as TT-034 is poised to enter the clinic in 2013.
Dr Suhy has held other distinguished roles with US-based biotechnology companies. He served as Principal Scientist at Antara Biosciences, where he was developing two molecular diagnostics platforms, based on electrochemistry and RFID tags as chip-based nucleic acid detection modalities.
He also led the Target Validation Group at PPD Discovery, a company with proprietary technology surrounding the use of genetic suppressor elements to identify ‘druggable’ genomic targets for large pharmaceutical companies.
Dr Suhy holds a BS in Biochemistry and Biophysics from the University of Pittsburgh, earned his PhD in Biochemistry, Molecular Biology and Cell Biology at Northwestern University, and conducted his post-doctoral work at Stanford University.
BMSN is going bigtime, Koos knows the people he must have on board. Its comming guys! $$$
BMSN. Post by Jobrano. BMSN
(0)
(0)RIVULET MEDIA INC. (RIVU) Stock Research Links
Scroll down for more posts ▼